Responses
Clinical/translational cancer immunotherapy
Original research
Single-arm trial of neoadjuvant ipilimumab plus nivolumab with chemoradiotherapy in patients with resectable and borderline resectable lung cancer: the INCREASE study
Compose a Response to This Article
Other responses
No responses have been published for this article.